Showing results (1-10 of 6) with videos related to
Sort By:
Pageof 1
Novartis Foundation Symposium|February 11, 2009
Bone marrow expressing a diabetes resistance MHC class II allele: diabetes deviation by chronic immune stimulationPeter Reifsnyder, William Schott, Darcy Pomerleau, et al.Experimental Hematology|July 24, 2002
Delayed administration of carrier marrow can decrease competition on donor stem cells during engraftment and maintain radioprotection of the hostBrian W Soper, Mark D Lessard, Craig D Jude, et al.Clinical Immunology (Orlando, Fla.)|February 21, 2006
Attenuation of murine lysosomal storage disease by allogeneic neonatal bone marrow transplantation using costimulatory blockade and donor lymphocyte infusion without myeloablationMark D Lessard, Travis L Alley, Jennifer L Proctor, et al.Experimental Hematology|October 31, 2003
Donor cell expansion is delayed following nonablative in utero transplantation to treat murine mucopolysaccharidosis type VIIJane E Barker, Adam J T Schuldt, Mark L Lessard, et al.Journal of Immunology (Baltimore, Md. : 1950)|September 10, 2003
Successful allogeneic neonatal bone marrow transplantation devoid of myeloablation requires costimulatory blockadeBrian W Soper, Mark D Lessard, Craig D Jude, et al.Blood Cells, Molecules & Diseases|February 6, 2004
Transplanted ER-MP12hi20-58med/hi myeloid progenitors produce resident macrophages from marrow that are therapeutic for lysosomal storage diseaseBrian W Soper, Ted M Duffy, Mark D Lessard, et al.Pageof 1